Can ALX Break The CD47 Curse?

The company presented promising Phase II data at the ASCO-GI conference for evorpacept, a drug whose target has been problematic for other drug makers.

gastric cancer
• Source: Shutterstock

Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to results that did not meet expectations.

The company presented data on 23 January at the American Society of Clinical Oncology Oncology’s Gastrointestinal Cancers Symposium from the...

More from Immuno-oncology

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.